Literature DB >> 15167953

[Compliance problems in therapy resistant hypertension].

Bernd-Christoph Werlemann1, Elmar Offers, Rainer Kolloch.   

Abstract

DEFINITION AND FREQUENCY: Hypertension may be termed refractory, when a therapeutic plan that has included nonpharmacologic treatment and the prescription of a triple drug combination in adequate doses including a diuretic, has failed to lower the blood pressure < 140/90 mmHg. True resistance can only be found in 2-5% of all hypertensive patients. CAUSES AND DIAGNOSIS: Pseudoresistance to antihypertensive therapy is common and often due to a suboptimal drug regime, interactions with other drugs or a secondary form of hypertension. It is estimated that in more than two thirds of patients with hypertension, poor compliance is at least part of the problem. Poor compliance is not easily detected by the physicians, and studies showed that they could not predict compliance with any more accuracy than if they were guessing. Factors for a poor compliance are lack of patient information about hypertension and its treatment, side effects of prescribed drugs, lack of teaching in the self-measurement of blood pressure and patient's dissatisfaction with the disease. Improvement of compliance can be achieved by selecting long-acting drugs or drug combinations. Structured teaching programs, as they become part of the Disease Management Programs (DMPs) in Germany can improve compliance as well. THERAPY: If noncompliance can be excluded, the dosage of antihypertensive drugs should be increased to a maximum if tolerated, or combinations of four or more drugs can be used, including drugs like minoxidil.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15167953     DOI: 10.1007/s00059-003-2523-7

Source DB:  PubMed          Journal:  Herz        ISSN: 0340-9937            Impact factor:   1.443


  3 in total

1.  The utility of an electronic adherence assessment device in type 2 diabetes mellitus: a pilot study of single medication.

Authors:  Nadir Kheir; William Greer; Adil Yousif; Hajer Al-Geed; Randa Al Okkah; Mahmoud Zirie; Amy Sandridge; Manal Zaidan
Journal:  Patient Prefer Adherence       Date:  2010-07-21       Impact factor: 2.711

2.  Persistence with antihypertensive treatments: results of a 3-year follow-up cohort study.

Authors:  Joerg Hasford; Detlef Schröder-Bernhardi; Marietta Rottenkolber; Karel Kostev; Gerhard Dietlein
Journal:  Eur J Clin Pharmacol       Date:  2007-08-14       Impact factor: 2.953

3.  Evaluation and treatment of resistant or difficult-to-control hypertension.

Authors:  David Wojciechowski; Vasilios Papademetriou; Charles Faselis; Ross Fletcher
Journal:  J Clin Hypertens (Greenwich)       Date:  2008-11       Impact factor: 3.738

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.